A recent study reveals that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who halt conventional lifestyle plans.
Published data in a prominent health publication shows that while overweight people frequently drop substantial amounts of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such medications need to be informed of the potential of rapid rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment weight within about a year and a half.
Weighing Treatments
The study, which looked at dozens of trials involving thousands of patients, compared the results of the injectable medications with other pills.
The team point out that people who shed pounds through lifestyle changes alone typically see a less rapid weight regain—around 0.1 kg a month—after stopping.
The Reason for the Quick Regain
Experts believe the mode of action of the drugs explains the accelerated regain.
These medications imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Issue?
Health authorities recommend the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, considering the significant potential of weight regain, the therapy is often ongoing.
This view is supported by pharmaceutical companies, who note that the findings "highlight the chronic nature of obesity," similar to managing diseases like hypertension.
Patient Accounts
Users who have stopped the jabs explain a intense resurgence of hunger.
"It felt as if something activating and you're instantly ravenous," said one woman.
This difficulty is worsened if patients have not adopted lasting dietary or behavioural modifications during therapy.
Growing Interest
Figures show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is more common among women compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, researchers caution that while the jabs are potent tools for weight loss, they are not a magic solution and maintained weight loss relies on combined behavioural changes.
